E
Avenue Therapeutics, Inc. ATXI
$0.9455 -$0.0245-2.53%
Recommendation
Sell
Prev Close
$0.97
Volume
20,615
Avg Vol (90D)
282,084
Market Cap
$1.85M
Dividend & Yield
--
52-Week Range
$0.9261 - $13.88
P/E (TTM)
--
EPS (TTM)
-$21.46
My Lists My Alerts
Rating
Reward
E
Very Weak
Risk
E+
Very Weak
Rating Factors
Growth Index
Fair
Efficiency Index
Very Weak
Solvency Index
Good
Total Return Index
Very Weak
Volatility Index
Very Weak
Dividend Index
--
Headlines
ARMISTICE CAPITAL, LLC Adjusts Holdings in Avenue Therapeutics Inc
2/15/2025 - GuruFocus
Ikarian Capital, LLC's Strategic Acquisition of Avenue Therapeutics Inc Shares
2/14/2025 - GuruFocus
Avenue Therapeutics (NASDAQ:ATXI) and Galectin Therapeutics (NASDAQ:GALT) Head to Head Review
1/13/2025 - Ticker Report
Avenue Therapeutics files $35M mixed securities shelf
12/4/2024 - TipRanks Financial Blog
Avenue Therapeutics files $35M mixed securities shelf
12/4/2024 - The Fly
Maxim Group Remains a Buy on Avenue Therapeutics (ATXI)
11/16/2024 - TipRanks Financial Blog
Avenue Therapeutics GAAP EPS of -$1.92 misses by $0.92
11/15/2024 - SeekingAlpha.com: All News
ARMISTICE CAPITAL, LLC Acquires Additional Shares in Avenue Therapeutics Inc
11/15/2024 - GuruFocus
Avenue Therapeutics reports Q3 EPS $(1.92) , consensus (94c)
11/14/2024 - TipRanks Financial Blog
Avenue Therapeutics reports Q3 EPS $(1.92) , consensus (94c)
11/14/2024 - The Fly
Avenue Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights
11/14/2024 - Globe Newswire
Avenue Therapeutics to Participate in Maxim Group's 2024 Healthcare Virtual Summit
10/9/2024 - Globe Newswire
Avenue Therapeutics to Participate in Upcoming Investor Conferences
9/3/2024 - Globe Newswire
Fortress Biotech Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights
8/13/2024 - Globe Newswire
ATXI Stock Earnings: Avenue Therapeutics Misses EPS for Q2 2024
8/10/2024 - InvestorPlace
Avenue Therapeutics Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights
8/9/2024 - Globe Newswire
Avenue Therapeutics, Inc. (NASDAQ:ATXI) Short Interest Update
7/1/2024 - Ticker Report
Head to Head Analysis: Avenue Therapeutics (NASDAQ:ATXI) versus Chimerix (NASDAQ:CMRX)
6/24/2024 - Zolmax
Comparing Avenue Therapeutics (NASDAQ:ATXI) and Chimerix (NASDAQ:CMRX)
6/21/2024 - Ticker Report
Avenue Therapeutics to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference
6/20/2024 - Globe Newswire
Avenue Therapeutics, Inc. (NASDAQ:ATXI) Short Interest Up 7.4% in May
6/19/2024 - Ticker Report
Avenue Therapeutics (ATXI) Gets a Buy from Maxim Group
6/7/2024 - TipRanks Financial Blog
Avenue Therapeutics Announces Last Patient Last Visit in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease)
5/16/2024 - Globe Newswire
Avenue Therapeutics GAAP EPS of $15.40 beats by $24.40
5/16/2024 - SeekingAlpha.com: All News
ATXI Stock Earnings: Avenue Therapeutics Misses EPS for Q1 2024
5/16/2024 - InvestorPlace
Income Statement
Total Revenue (TTM)
--
EBITDA (TTM)
--
EBIT (TTM)
-$11.81M
Net Income (TTM)
-$9.47M
Balance Sheet
Total Assets (Q)
$2.63M
Total Debt (Q)
$0.00
Total Liabilities (Q)
$973.00K
Book Value Per Share (Q)
$1.63
Cash Flow
Cash from Operations (TTM)
-$10.59M
Cash from Investing (TTM)
$0.00
Cash from Financing (TTM)
$13.02M
Net Change in Cash (TTM)
$2.44M
Filings
Filing Date
Thursday, November 14, 2024
Period Date
Monday, September 30, 2024
Next Filing
Week of Mar 17 and 21 (est)
Price History
Loading...
Beta
0.59
7-Day Total Return
-6.27%
30-Day Total Return
-31.98%
60-Day Total Return
-49.17%
90-Day Total Return
-61.41%
Year to Date Total Return
-51.01%
1-Year Total Return
-92.79%
2-Year Total Return
-98.88%
3-Year Total Return
-99.88%
5-Year Total Return
-99.99%
52-week Low
Mar 06, 2025 - $0.9261
52-week High
Mar 12, 2024 - $13.88
Valuation
Market Cap
$1.85M - Nano Cap
Enterprise Value
-$1.70M
Price/Sales (TTM)
--
Price/Book (Q)
0.60
Dividends and Shares
Shares Outstanding
1.60M
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
www.avenuetx.com
Phone Number
781 652 4500
Address
1111 Kane Concourse
Bay Harbor Islands, FL 33154
Country
United States
Year Founded
2015
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Avenue Therapeutics, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of neurologic diseases. Its product candidates... more
NASDAQ 03/12/2025 3:52PM Eastern Quotes delayed
Weiss Ratings